This article only represents the author's own views.
Stock market rallies in Hong Kong and Mainland China since late September have delivered a needed shot in the arm for China’s long-dormant innovative drug sector. After four years of painful adjustment, valuations are suddenly attractive once again, with the CSI Hong Kong Innovative Drug Index up 26% in September alone.
While some of those gains went back during a broader market pause in early October, innovative drug makers with stable returns and strong overseas prospects continued to attract attention. One of those is Everest Medicines Ltd. (1952.HK), which focuses on auto-immune disease and mRNA-based treatments.
您已閱讀9%（675字），剩餘91%（6939字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。